Suvizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | HIV-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Suvizumab is an experimental antiviral drug and immunomodulator. It is a monoclonal antibody that binds to HIV-1.[1]
References
- ^ "Proposed List number 102 of International Nonproprietary Names" (PDF). WHO Drug Information. 23 (4). Geneva: World Health Organization: 344. 2009. ISSN 1010-9609.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Short description with empty Wikidata description
- Drugs not assigned an ATC code
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugs that are a monoclonal antibody
- Monoclonal antibodies
- Experimental antiviral drugs
- Antiinfective agent stubs
- Monoclonal antibody stubs